natgillin/translations-raw huggingface dataset:
EndolucinBeta is not a medicine and it is not intended to be used on its own. 
EndolucinBeta ni zdravilo in se ne sme uporabljati samo.
Please read the package leaflet of that medicine carefully. 
Natančno preberite navodilo za uporabo teh zdravil.
The volume depends on the quantity of medicine combined with EndolucinBeta required for administration by the nuclear medicine doctor. 
Prostornina je odvisna od količine zdravila, kombiniranega z radionuklidnim predhodnikom EndolucinBeta, ki jo zdravnik nuklearne medicine potrebuje za dajanje.
The complexing agent and other reagents should be added to the vial with Lutetium (177Lu) chloride. 
Kompleksirajoči reagent in druge reagente je treba dodati v vialo z lutecijevim (177Lu) kloridom.
Radiolabelled somatostatin analogues are excreted by the kidney. 
Radioaktivno označeni analogi somatostatina se izločajo skozi ledvice.
No interaction studies of Lutetium (177Lu) chloride with other medicinal products have been performed. 
Študij medsebojnega delovanja lutecijevega (177Lu) klorida z drugimi zdravili niso izvedli.
- if you are allergic to Lutetium (177Lu) chloride or any of the other ingredients of this medicine 
- če ste alergični na lutecijev (177Lu) klorid ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
177Lu-chloride contains 2.4 µg Lutetium, corresponding to a human dose of 0.034 µg/kg. 
Visok odmerek 10 GBq lutecijevega (177Lu) klorida vsebuje 2,4 µg lutecija, kar ustreza človeškemu odmerku 0,034 µg/kg.
Point-source approximation shows that the average dose rate experienced 20 hours after administration of a dose of 7.3 GBq EndolucinBeta labelled radiopharmaceutical (residual radioactivity 1.5 GBq) by a person at 1 meter distance from the patient's body centre with an abdominal radius of 15 cm is 3.5 µSv/h. 
Zaščita pred sevanjem Približek s točkovnim virom kaže, da pri osebi na razdalji enega metra od središča telesa bolnika s polmerom trebuha 15 cm, ki je pred 20 urami prejel odmerek 7,3 GBq radiofarmaka, označenega z radionuklidnim predhodnikom EndolucinBeta (preostala radioaktivnost 1,5 GBq), povprečna stopnja odmerka sevanja znaša 3,5 µSv/h.
The vials are placed into a lead container for protective shielding and packed in a metallic can and an outer carton. 
Viale so v svinčenem vsebniku, ki predstavlja varovalni ščit, in so pakirane v kovinski posodi in zunanji škatli.
However, a post-exposure interval > 1 hour does not preclude the administration and effective action of chelator with reduced efficiency.Intravenous administration should not be protracted over more than 2 hours. 
Vendar pa dajanje in učinkovito delovanje kelatorja z zmanjšano učinkovitostjo pri časovnem razmiku po izpostavljenosti, ki je > 1 ure, nista izključeni.
The produced Ytterbium (177Yb) with a half-life of 1.9 h decays to Lutetium (177Lu). 
Pridobljeni iterbij (177Yb) z razpolovno dobo 1,9 ure razpade na lutecij (177Lu).
EndolucinBeta is not to be administered directly to the patient, but must be used for the radiolabelling of carrier molecules, such as monoclonal antibodies, peptides, vitamins or other substrates. 
Radionuklidni predhodnik EndolucinBeta se ne sme dajati neposredno bolniku, temveč ga je treba uporabiti za radioaktivno označevanje nosilnih molekul, kot so monoklonska protitelesa, peptidi,
Colourless type I glass 2 mL or 10 mL vial with a V-shaped and flat bottom, respectively, with a bromobutyl stopper, closed with an aluminium seal. 
Brezbarvna steklena viala tipa I prostornine 2 ml ali 10 ml, katere dno ima obliko črke V oziroma je plosko, z brombutilnim zamaškom in zaprta z aluminijastim tesnilom.
The nuclear medicine doctor supervising the procedure will decide on the quantity of a medicine radiolabelled with EndolucinBeta to be used in your case. 
Zdravnik nuklearne medicine, ki bo nadzoroval postopek, bo določil količino zdravila, radioaktivno označenega z radionuklidnim predhodnikom EndolucinBeta, ki bo uporabljena pri vas.
Treatment with Lutetium (177Lu) may cause tumour lysis syndrome, due to the rapid breakdown of tumour cells. 
Zdravljenje z lutecijem (177Lu) lahko povzroči sindrom tumorske lize zaradi hitre razgradnje tumorskih celic.
Individual benefit/risk justification 
Presoja razmerja med koristmi in tveganji pri posameznem bolniku
It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (177Lu) chloride. 
Uporablja se samo za radioaktivno označevanje nosilnih molekul, posebej razvitih in odobrenih za radioaktivno označevanje z lutecijevim (177Lu) kloridom.
ANNEX IV SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION(S) 
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA SPREMEMBO POGOJEV DOVOLJENJ ZA
You will not have to store this medicine. 
Tega radionuklidnega predhodnika vam ne bo treba shranjevati.
Information on radiation dosimetry of each different medicinal product following administration of the radiolabelled preparation is available in the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled. 
Informacije o dozimetriji sevanja vsakega različnega zdravila po dajanju radioaktivno označenega pripravka so na voljo v povzetku glavnih značilnosti zdravila/navodilu za uporabo posameznega radioaktivno označenega zdravila.
The effective dose to a 73.7 kg adult resulting from an inadvertently injected intravenous activity of 1 GBq would be 534 mSv. 
Pri odraslem s telesno maso 73,7 kg znaša raven odmerka, pri katerem se pokaže učinek in ki izvira iz nenamerno intravensko injicirane aktivnosti 1 GBq, 534 mSv.
Lutetium (177Lu) chloride is produced by the irradiation of highly enriched (> 99 %) Ytterbium (176Yb) in neutron sources with a thermal neutron flux between 1013 and 1016 cm−2 s−1. 
Lutecijev (177Lu) klorid nastane z obsevanjem visoko obogatenega (> 99 %) iterbija (176Yb) v virih nevtronov s tokom termičnih nevtronov med 1013
In the male and female rat, following intravenous administration, Lutetium (177Lu) chloride is rapidly cleared from the blood: at 5 min post injection, only 1.52 % of the injected activity (%ID) is found in blood (corresponding to 0.08 %ID/g) and no activity above background levels remains 1 hour post dose. 
Pri podganjih samcih in samicah se lutecijev (177Lu) klorid po intravenskem dajanju hitro izloči iz krvi: 5 minut po injiciranju je v krvi najdene le 1,52 % injicirane aktivnosti (% ID) (kar ustreza
In all cases, the risk of the radiation is outweighed by the potential benefit of receiving the radiolabelled medicine. 
V vsakem primeru možne koristi zaradi prejema radioaktivno označenega zdravila odtehtajo tveganje zaradi sevanja.
Each pack contains 1 vial placed into a lead container for protective shielding and packed in a metallic can and an outer carton. 
Eno pakiranje vsebuje eno vialo v svinčenem vsebniku, ki predstavlja varovalni ščit, pakirano v kovinski posodi in zunanji škatli.
The dosimetry table below is presented in order to evaluate the contribution of non-conjugated Lutetium (177Lu) to the radiation dose following the administration of a Lutetium (177Lu)-labelled medicinal product or resulting from an accidental intravenous injection of EndolucinBeta. 
Spodnja preglednica dozimetrije prikazuje ocenjeni prispevek nekonjugiranega lutecija (177Lu) k odmerku sevanja, ki sledi dajanju z lutecijem (177Lu) označenega zdravila ali je rezultat nenamernega intravenskega injiciranja radionuklidnega predhodnika EndolucinBeta.
The presence of free Lutetium (177Lu) chloride in the body after an inadvertent administration of EndolucinBeta will lead to increased bone marrow toxicity and haematopoietic stem cell damage. 
Prisotnost prostega lutecijevega (177Lu) klorida v telesu po nenamernem dajanju radionuklidnega predhodnika EndolucinBeta povzroči povečano toksičnost za kostni mozeg in okvaro hematopoetskih matičnih celic.
After one hour, the amount in the liver is 9.56 % of the injected activity per gram (%ID/g) and in the spleen 5.26 %ID/g. 
injicirane aktivnosti na gram (% ID/g), v vranici pa 5,26 % ID/g.
The toxicity of free Lutetium (177Lu) due to in-vivo release from the labelled biomolecule in the body during therapy could be reduced by post-administration of chelating agents. 
Toksičnost prostega lutecija (177Lu) zaradi sprostitve in vivo iz označene biomolekule v telesu med zdravljenjem je mogoče zmanjšati z naknadnim dajanjem kelatorjev.
EndolucinBeta is a radiopharmaceutical precursor, and it is not intended for direct use in patients. 
EndolucinBeta je radionuklidni predhodnik in ni namenjen za neposredno uporabo pri bolnikih.
EndolucinBeta is intended for in vitro radiolabelling of medicinal products which are subsequently administered by the approved route. 
Radionuklidni predhodnik EndolucinBeta je namenjen za radioaktivno označevanje zdravil in vitro, ki se nato dajejo v skladu z odobreno potjo uporabe.
Treatment with Lutetium (177Lu) may cause disturbances of liver function. 
Zdravljenje z lutecijem (177Lu) lahko povzroči motnje delovanja jeter.
Tell your doctor if you feel faint or dizzy or experience flushing or diarrhoea following your treatment. 
Obvestite zdravnika, če imate po zdravljenj občutek omedlevice ali omotice ali če imate vročinske oblive ali drisko.
EndolucinBeta is a radiopharmaceutical precursor, solution. 
EndolucinBeta je radionuklidni predhodnik, raztopina.
Please read the package leaflet of that medicine. 
Preberite navodilo za uporabo tega zdravila.
EndolucinBeta is only to be used by specialists experienced with in vitro radiolabelling. 
Radionuklidni predhodnik EndolucinBeta smejo uporabljati le zdravniki specialisti, ki imajo izkušnje na področju radioaktivnega označevanja in vitro.
5 years old (19.8 kg) 
Osebe, stare 5 let (19,8 kg)
The European Medicines Agency has waived the obligation to submit the results of the studies with EndolucinBeta in all subsets of the paediatric population on grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients. 
Pediatrična populacija Ker zadevno zdravilo v primerjavi z obstoječimi zdravljenji za pediatrične bolnike ne pomeni pomembne terapevtske koristi, je Evropska agencija za zdravila odstopila od zahteve za predložitev rezultatov študij z radionuklidnim predhodnikom EndolucinBeta za vse podskupine pediatrične populacije.
The carrier medicine then takes the EndolucinBeta to the disease site in the body. 
Nosilno zdravilo nato prenese radionuklidni predhodnik EndolucinBeta na obolelo mesto v telesu.
Distribution after inadvertent intravenous administration of Lutetium (177Lu) chloride 
Porazdelitev po nenamernem intravenskem dajanju lutecijevega (177Lu) klorida
During peptide-receptor radionuclide therapy for neuroendocrine tumours, radiolabelled somatostatin analogues are excreted by the kidneys. 
Med radionuklidno terapijo s peptidnimi receptorji za nevroendokrine tumorje ledvice izločajo radioaktivno označene somatostatinske analoge.
Other medicines and medicines radiolabelled with EndolucinBeta 
Druga zdravila in zdravila, radioaktivno označena z radionuklidnim predhodnikom EndolucinBeta
The quantity of EndolucinBeta required for radiolabelling and the quantity of Lutetium (177Lu)-labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use. 
Količina radionuklidnega predhodnika EndolucinBeta, potrebna za radioaktivno označevanje, in količina z lutecijem (177Lu) označenega zdravila, ki je nato uporabljeno, sta odvisni od radioaktivno označenega zdravila in njegove predvidene uporabe.
There have been reports of carcinoid crisis and other syndromes associated with release of hormones from functional neuroendocrine tumours following Lutetium (177Lu) peptide receptor radionuclide therapy, which may be related to irradiation of tumour cells. 
Sindromi sproščanja hormonov Obstajajo poročila o karcinoidni krizi in drugih sindromih, povezanih s sproščanjem hormonov iz funkcionalnih nevroendokrinih tumorjev po zdravljenju z radionuklidno terapijo s peptidnimi receptorji (PRRT) za lutecij (177Lu), ki so lahko povezani z obsevanjem tumorskih celic.
Renal irradiation 
Sevanje v ledvicah
Your doctor will therefore take a blood test to measure your kidney function before you start and during treatment. 
Zdravnik bo zato pred začetkom zdravljenja in med njim opravljal krvno preiskavo za merjenje delovanja vaših ledvic.
The radiation dose received by various organs following intravenous administration of a Lutetium (177Lu)-labelled medicinal product is dependent on the specific molecule being radiolabelled. 
Odmerki sevanja, ki jih prejmejo različni organi po intravenskem dajanju z lutecijem (177Lu) označenega zdravila, so odvisni od posamezne molekule, ki se radioaktivno označuje.
Such information will be supplied in the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled. 
Te informacije bodo navedene v povzetku glavnih značilnosti zdravila/navodilu za uporabo zdravila, ki bo radioaktivno označevano.
A blood count should be taken at baseline and monitored regularly during treatment, in accordance with clinical guidance. 
V skladu s kliničnimi smernicami je treba ob izhodišču napraviti krvno sliko in jo med zdravljenjem redno spremljati.
Your doctor will take a blood test to monitor your liver function during treatment. 
Zdravnik vam bo med zdravljenjem opravil krvno preiskavo za spremljanje delovanja jeter.
The intraperitoneal LD50 in mice was found to be approximately 315 mg/kg. 
Ugotovljeno je bilo, da je intraperitonealna LD50 pri miših približno
Read all of this leaflet carefully before you are given the medicine combined with EndolucinBeta because it contains important information for you. 
EndolucinBeta, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
Taking into account the PRAC Assessment Report on the PSUR(s) for Lutetium (177Lu) chloride, the scientific conclusions of the CHMP are as follows: 
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni redno posodobljenih poročil o varnosti zdravila (PSUR) za lutecijev (177Lu) klorid je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
The use of a medicine radiolabelled with EndolucinBeta does involve exposure to radioactivity. 
Pri uporabi zdravila, radioaktivno označenega z radionuklidnim predhodnikom EndolucinBeta, je prisotna izpostavljenost radioaktivnosti.
Neoplasms benign, malignant and unspecified (including cysts and polyps): common: Refractory cytopenia with multilineage dysplasia (Myelodysplastic syndrome) (see section 4.4) uncommon: Acute myeloid leukaemia (see section 4.4) Skin and subcutaneous tissue disorders: very common: Alopecia 
Pogosti: refraktarna citopenija z displazijo več celičnih linij (mielodisplastični sindrom) (glejte poglavje 4.4) Občasni: akutna mieloična levkemija (glejte poglavje 4.4)
Muscle 
Mišice
EXP:{DD/MM/YYYY, hh:00 CET} 
EXP:{DD/MM/LLLL, uu:00 CET}
EXP: {DD/MM/YYYY, hh:00 CET} 
EXP: {DD/MM/LLLL, uu:00 CET}
Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials. 
Radiofarmaki bodo shranjeni v skladu z nacionalnimi predpisi o radioaktivnih snoveh.
- If you get any side effects, talk to your nuclear medicine doctor. 
- Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom nuklearne medicine.
Urinary Bladder Wall Uterus 
Ščitnica Stena sečnega mehurja
ANNEX II A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA
Therefore, Lutetium metal-ion toxicity of EndolucinBeta (177Lu)-labelled medicinal products can be excluded. 
Zato je mogoče toksičnost kovinskih ionov lutecija pri zdravilih, označenih z radionuklidnim predhodnikom EndolucinBeta (177Lu), izključiti.
EndolucinBeta 40 GBq/mL radiopharmaceutical precursor, solution 
EndolucinBeta 40 GBq/ml radionuklidni predhodnik, raztopina
After the medicine radiolablelled with EndolucinBeta is administered, it will deliver certain amounts of ionising radiation (radioactivity) which can induce a certain risk of cancer and development of hereditary defects. 
boste prejeli določene količine ionizirajočega sevanja (radioaktivnosti), ki prinaša določeno tveganje za raka in razvoj dednih okvar.
1 mL sterile solution contains 40 GBq Lutetium (177Lu) chloride on the activity reference time (corresponding to 10 micrograms of Lutetium (177Lu) as Lutetium (177Lu) chloride). 
1 ml sterilne raztopine vsebuje 40 GBq lutecijevega (177Lu) klorida v referenčnem času aktivnosti (kar ustreza 10 mikrogramom lutecija (177Lu) v obliki lutecijevega (177Lu) klorida).
Hydrochloric acid solution 
Raztopina klorovodikove kisline
What EndolucinBeta is and what it is used for 
Kaj je radionuklidni predhodnik EndolucinBeta in za kaj ga uporabljamo
Storage should be in accordance with local regulations for radioactive substances. 
Shranjujte v skladu z lokalnimi predpisi o radioaktivnih snoveh.
Table 1: Lutetium (177Lu) principle radiation emission data 
Preglednica 1: Podatki o glavnih emisijah sevanja lutecija (177Lu)
These carrier medicines have been specially developed for use with Lutetium (177Lu) chloride and may be substances that have been designed to recognise a particular type of cell in the body. 
Ta nosilna zdravila so bila posebej razvita za uporabo z lutecijevim (177Lu) kloridom in so lahko snovi,
Blood and lymphatic system disorders: very common: Anaemia, thrombocytopenia, leukopenia and lymphopenia Endocrine disorders: not known: Carcinoid crisis 
Zelo pogosti: anemija, trombocitopenija, levkopenija in limfopenija
- The active substance is Lutetium (177Lu) chloride. 
- Zdravilna učinkovina je lutecijev (177Lu) klorid.
Each 2 mL vial contains an activity ranging from 3 - 80 GBq, corresponding to 0.73 - 19 micrograms of Lutetium (177Lu), at ART. 
V eni 2-mililitrski viali je aktivnost v razponu od 3 do 80 GBq, kar ustreza 0,73-19 mikrogramom lutecija (177Lu) v času ART. Prostornina znaša 0,075-2 ml.
Effects on ability to drive and to use machines following treatment by Lutetium (177Lu)-labelled medicinal products will be specified in the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled. 
Vplivi na sposobnost vožnje in upravljanja strojev po zdravljenju z zdravili, označenimi z lutecijem (177Lu), bodo podrobno navedeni v povzetku glavnih značilnosti zdravila/navodilu za uporabo zdravila, ki bo radioaktivno označeno.
If you get any side effects, talk to your nuclear medicine doctor. 
Če opazite katerega koli izmed neželenih učinkov, se posvetujte z zdravnikom nuklearne medicine.
What EndolucinBeta is and what it is used for What you need to know before the medicine radiolabelled with EndolucinBeta is used How the medicine radiolabelled with EndolucinBeta is used Possible side effects 
Kaj je radionuklidni predhodnik EndolucinBeta in za kaj ga uporabljamo Kaj morate vedeti, preden vam bodo dali zdravilo, radioaktivno označeno z radionuklidnim predhodnikom EndolucinBeta
The nuclear medicine doctor will inform you if you need to take any special precautions after receiving the medicine radiolabelled with EndolucinBeta. 
Zdravnik nuklearne medicine vas bo obvestil, ali morate po prejemu zdravila, radioaktivno označenega z radionuklidnim predhodnikom EndolucinBeta, upoštevati kakršne koli posebne previdnostne ukrepe.
Table 2: Estimated organ absorbed radiation doses and effective doses (mSv/MBq) after inadvertent intravenous administration of 177LuCl3 for various human age classes, based on data collected in rats (n = 24) 
(mSv/MBq) po nenamernem intravenskem dajanju 177LuCl3 za različne starostne skupine ljudi, glede na podatke, zbrane pri podganah (n = 24)
Radiation nephropathy has been reported following peptide receptor radionuclide therapy for neuroendocrine tumours using other radioisotopes. 
Po radionuklidni terapiji za nevroendokrine tumorje s peptidnimi receptorji so pri uporabi drugih radioaktivnih izotopov poročali o radiacijski nefropatiji.
Five cases of tumour lysis syndrome (TLS) were identified in the scientific literature in association with Lu-177 based radioligand therapy (RLT). 
V znanstveni literaturi so v povezavi z radioligandno terapijo (RLT) z Lu-177 poročali o petih primerih sindroma tumorske lize (TLS).
EndolucinBeta 40 GBq/mL radiopharmaceutical precursor, solution Lutetium (177Lu) chloride 
EndolucinBeta 40 GBq/ml radionuklidni predhodnik, raztopina lutecijev (177Lu) klorid
Lutetium (177Lu) emits β-particles of moderate maximum energy (0.498 MeV) with a maximum tissue penetration of approximately 2 mm. Lutetium (177Lu) also emits low-energy γ-rays which allow scintigraphic, biodistribution and dosimetry studies with the same Lutetium (177Lu)-labelled medicinal products. 
Lutecij (177Lu) oddaja tudi nizkoenergijske žarke γ, ki omogočajo scintigrafske, biodistribucijske in dozimetrične študije z istimi zdravili, označenimi z lutecijem (177Lu).
- The other ingredient is hydrochloric acid solution. 
- Druga sestavina radionuklidnega predhodnika je raztopina klorovodikove kisline.
METHOD AND ROUTE(S) OF ADMINISTRATION 
POSTOPEK IN POT(-I) UPORABE ZDRAVILA
Gastrointestinal disorders: very common: Nausea, vomiting 
Zelo pogosti: navzea, bruhanje
For more information, refer to the package leaflet of the particular medicinal product to be radiolabelled. 
Za več informacij glejte navodilo za uporabo zdravila, ki bo radioaktivno označeno.
Excipient: Hydrochloric acid solution 
Pomožna snov: raztopina klorovodikove kisline
Small Intestine Stomach Wall ULI Wall 
Stena žolčnega mehurja Stena spodnjega dela debelega črevesa Tanko črevo Želodčna stena
EndolucinBeta must be used only in combination with another medicine (carrier medicine) which has been specifically developed and authorised for being combined with Lutetium (177Lu) chloride. 
Dajanje zdravila, radioaktivno označenega z radionuklidnim predhodnikom EndolucinBeta, in izvedba postopka EndolucinBeta se lahko uporablja le skupaj z drugim zdravilom (nosilnim zdravilom), ki je bilo posebej razvito in odobreno za kombiniranje z lutecijevim (177Lu) kloridom.
EndolucinBeta must not be used after the expiry date and time which is stated on the label after EXP. EndolucinBeta will be stored in the original package that provides protection from radiation. 
Radionuklidnega predhodnika EndolucinBeta ne smete uporabljati po datumu in času izteka roka uporabnosti, ki sta navedena na nalepki poleg oznake EXP.
Gamma 208.3662 * mean energies are listed for beta particles Lutetium (177Lu) decays by emission of beta radiation to stable Hafnium (177Hf). 
Lutecij (177Lu) z emisijo sevanja beta razpade na stabilni hafnij (177Hf).
What EndolucinBeta looks like and contents of the pack 
Izgled radionuklidnega predhodnika EndolucinBeta in vsebina pakiranja
If you are breast-feeding 
Če ste noseči
Cases of hepatotoxicity have been reported in the post-marketing setting and in the literature in patients with liver metastases undergoing treatment with Lutetium (177Lu) peptide receptor radionuclide therapy for neuroendocrine tumours. 
Po prihodu zdravila na trg in v literaturi, pri bolnikih z metastazami jeter, ki prejemajo radionuklidno terapijo s peptidnimi receptorji (PRRT) za lutecij (177Lu) za zdravljenje nevroendokrinih tumorjev, so poročali o primerih hepatotoksičnosti.
Because Lutetium (177Lu) can sometimes affect your blood cells, your doctor will do blood tests before you start and at regular intervals during treatment. 
Lutecij (177Lu) lahko včasih vpliva na vaše krvne celice,
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL (2 mL, 10 mL) 
OVOJNINAH VIALA (2 ml, 10 ml)
VOLUME: 
Številka serije: